No Yes Ok

Archive

« Older Entries Newer Entries »

arGEN-X to Present at Upcoming Ninth Annual PEGS 2013 Friday, April 26th, 2013
Presentations will highlight significant progress made towards development of novel therapeutic antibodies Breda, the Netherlands and Ghent, Belgium April 26, 2013 – arGEN-X, a clinical stage biopharmaceutical compa [...]
arGEN-X advances ARGX-113 into preclinical development for autoimmune disorders Wednesday, April 24th, 2013
First program based on proprietary ABDEG™ technology to promote degradation and clearance of disease-causing autoantibodies Breda, the Netherlands and Ghent, Belgium April 24, 2013 – arGEN-X, a clinical stage biop [...]
Better diagnosis of acute heart failure using Pronota’s novel biomarker Thursday, April 18th, 2013
Two independent validation studies demonstrate that Pronota’s biomarker CD146 significantly improves the diagnosis of acute heart failure for patients with shortness of breath. The biomarker, measured in blood, prov [...]
ActoGeniX closes EUR 10.7 million financing round Thursday, April 18th, 2013
ActoGeniX, a clinical stage biopharmaceutical company, successfully closed a Series B equity financing round, raising EUR 10.7 million (USD 14 million). This financing round was led by new investor Saffelberg Investments [...]
LSP sounds the opening bell of the NYSE Euronext Stock Exchange Friday, April 12th, 2013
https://www.youtube.com/watch?v=0zdV3vCSfXE&feature=player_embedded See also www.aex.nl [...]
IlluminOss Medical Names Dirk Kuyper as Chief Executive Officer Tuesday, April 9th, 2013
New CEO Hired to Initiate Commercial Activities in Europe for its Photodynamic Bone Stabilization System and to Secure Regulatory Approval in the US market East Providence, RI. (April 9, 2013) – IlluminOss Medical, [...]
arGEN-X announces preclinical development of ARGX-112 for dermatology Monday, March 25th, 2013
ARGX-112 targets IL22R1, a novel target involved in chronic skin inflammation Breda, the Netherlands and Ghent, Belgium March 25, 2013 – arGEN-X, a clinical stage biopharmaceutical company specialized in the discove [...]
TiGenix to obtain national reimbursement in Spain for its innovative cartilage therapy ChondroCelect® Tuesday, March 12th, 2013
Leuven (BELGIUM), Madrid (SPAIN) – March 12, 2013 – TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, announced today that it was informed by the Spanish Health Authority that its innovative c [...]
Zealand Pharma announces pipeline update Friday, March 8th, 2013
Copenhagen, 2013-03-08 08:28 CET (GLOBE NEWSWIRE) -- ─ First European sales of Lyxumia® (lixisenatide): Zealand-invented peptide medicine now available for adult diabetes patients ─ Elsiglutide for chemotherap [...]
Merus Further Expands R&D Capacity Thursday, March 7th, 2013
Company Contracts R&D Service Provider FairJourney Biologics Utrecht, The Netherlands, March 7, 2013 – Merus B.V., a biopharmaceutical company focusing on innovative human antibody therapeutics, today announced that [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
Follow us

No Yes Ok

Archive

« Older Entries Newer Entries »

arGEN-X to Present at Upcoming Ninth Annual PEGS 2013 Friday, April 26th, 2013
Presentations will highlight significant progress made towards development of novel therapeutic antibodies Breda, the Netherlands and Ghent, Belgium April 26, 2013 – arGEN-X, a clinical stage biopharmaceutical compa [...]
arGEN-X advances ARGX-113 into preclinical development for autoimmune disorders Wednesday, April 24th, 2013
First program based on proprietary ABDEG™ technology to promote degradation and clearance of disease-causing autoantibodies Breda, the Netherlands and Ghent, Belgium April 24, 2013 – arGEN-X, a clinical stage biop [...]
Better diagnosis of acute heart failure using Pronota’s novel biomarker Thursday, April 18th, 2013
Two independent validation studies demonstrate that Pronota’s biomarker CD146 significantly improves the diagnosis of acute heart failure for patients with shortness of breath. The biomarker, measured in blood, prov [...]
ActoGeniX closes EUR 10.7 million financing round Thursday, April 18th, 2013
ActoGeniX, a clinical stage biopharmaceutical company, successfully closed a Series B equity financing round, raising EUR 10.7 million (USD 14 million). This financing round was led by new investor Saffelberg Investments [...]
LSP sounds the opening bell of the NYSE Euronext Stock Exchange Friday, April 12th, 2013
https://www.youtube.com/watch?v=0zdV3vCSfXE&feature=player_embedded See also www.aex.nl [...]
IlluminOss Medical Names Dirk Kuyper as Chief Executive Officer Tuesday, April 9th, 2013
New CEO Hired to Initiate Commercial Activities in Europe for its Photodynamic Bone Stabilization System and to Secure Regulatory Approval in the US market East Providence, RI. (April 9, 2013) – IlluminOss Medical, [...]
arGEN-X announces preclinical development of ARGX-112 for dermatology Monday, March 25th, 2013
ARGX-112 targets IL22R1, a novel target involved in chronic skin inflammation Breda, the Netherlands and Ghent, Belgium March 25, 2013 – arGEN-X, a clinical stage biopharmaceutical company specialized in the discove [...]
TiGenix to obtain national reimbursement in Spain for its innovative cartilage therapy ChondroCelect® Tuesday, March 12th, 2013
Leuven (BELGIUM), Madrid (SPAIN) – March 12, 2013 – TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, announced today that it was informed by the Spanish Health Authority that its innovative c [...]
Zealand Pharma announces pipeline update Friday, March 8th, 2013
Copenhagen, 2013-03-08 08:28 CET (GLOBE NEWSWIRE) -- ─ First European sales of Lyxumia® (lixisenatide): Zealand-invented peptide medicine now available for adult diabetes patients ─ Elsiglutide for chemotherap [...]
Merus Further Expands R&D Capacity Thursday, March 7th, 2013
Company Contracts R&D Service Provider FairJourney Biologics Utrecht, The Netherlands, March 7, 2013 – Merus B.V., a biopharmaceutical company focusing on innovative human antibody therapeutics, today announced that [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
X

MONTHLY REPORTS

Here you can subscribe for the monthly report of the LSP Life Sciences Fund